Breast Cancer Metastasis Suppressor-1 differentially regulates expression of multiple genes, leading to metastasis suppression without affecting orthotopic tumor growth.
INTRODUCTION
Distant metastasis is the main cause of morbidity and mortality in most cancer patients and most breast cancer-related deaths occur as a result of treatment failure of metastases [1] . Therefore, it is important to better understand the molecular mechanisms related to metastasis and to develop early therapeutic approaches in order to prevent the dissemination of tumor cells; this will come from better understanding of the metastatic process, including how molecular factors, such as metastasis suppressors, contribute to this process [2] . Metastasis suppressors, by definition, inhibit metastasis at any step of the metastatic cascade without blocking primary tumor growth by regulating signaling pathways that inhibit proliferation, cell migration and growth at the secondary site [3] .
The isolation and functional characterization of breast-cancer metastasis suppressor 1 (BRMS1), as a novel mediator of metastasis suppression in human breast carcinoma was first described in 2000 [4] . This gene encodes for a predominantly nuclear protein that differentially regulates the expression of multiple genes, leading to suppression of metastasis without blocking orthotopic tumor growth. The murine version, Brms1, also suppresses metastasis and exhibits a high level of homology to the human gene [5] . By interacting with large chromatin remodelling complexes, BRMS1 regulates chromatin status and therefore modulates the expression of genes functioning in cell apoptosis, cell-cell communication and cell migration [6] [7] [8] [9] . In this way, upon forced expression in metastatic cells, a nearly complete suppression of metastasis is noted without preventing primary tumor growth [10] . Additionally, BRMS1 inhibits the activity of NFκB, a well-known transcription factor that plays significant roles in tumor progression, and coordinately regulates the expression of metastasis-associated microRNAs known as metastamirs [11] .
In vitro, BRMS1 expression decreased cancer cell survival under stress conditions (hypoxia), increased anoikis, and decreased the ability of cancer cells to adhere [12] .
Recent results point toward a possible link between BRMS1 expression and apoptosis in human breast cancer through a relationship with the expression of genes belonging to the X-chromosome RBM family [13] . Cook et al have recently shown that cell type-specific over-expression of Brms1 is important for Brms1-mediated metastasis suppression [14] . BRMS1 cellular location is important for its effects as a metastasis suppressor, with nuclear vs. cytoplasmic expression associated with invasive and metastatic capacity in a cell type-specific manner [15, 16] .
Circulating tumor cells (CTC) are prognostic in a variety of human cancers and have been proposed as a so-called 'liquid biopsy' for follow-up examinations [17] . The presence of CTC in peripheral blood appears to be an early indicator of metastasis and may indicate tumor spread prior to clinical symptoms or detection by imaging [17] .
Research on CTC is gaining attention because they are defined targets for understanding the metastatic process [18] . CTC molecular characterization has the potential to provide important information regarding the cancer cells which could be utilized to guide individualized targeted treatments [19] .
We recently showed that BRMS1 promoter is methylated in CTC isolated from peripheral blood from both operable and metastatic breast cancer patients [20] . outcome has not been previously reported. In this study, we aimed to examine the clinical significance of BRMS1 promoter methylation in early breast cancer, using FFPE and CTC in patients with long follow-up.
MATERIALS AND METHODS
The outline of the workflow of our study is shown in Figure 1 .
Clinical samples
We evaluated: a) BRMS1 promoter methylation by methylation specific PCR in a total number of 118 breast tissue samples b) BRMS1 expression and BRMS1 promoter methylation in CTC from 39 corresponding peripheral blood cytospin samples. More specifically: a) primary breast cancer tissues (FFPEs): 84 formalin fixed paraffin-embedded tissue samples (FFPEs) were available from patients with early breast cancer with a known clinical outcome and a median follow-up of 121 months (range 58-157). FFPE sections were also available from 5 pairs of breast tumors and their surrounding noncancerous tissues and 14 non-cancerous breast tissues (histologically cancer-free specimens from reduction mammoplasty) were used as a control set. 10 benign fibroadenomas, were also included as a separate benign tumor group. b) CTC (cytospins): 39 blood samples obtained before the initiation of adjuvant chemotherapy from the same patients with early breast cancer were analyzed.
Peripheral blood (10 ml in EDTA) was drawn from the middle of vein puncture after the first 5 ml of blood were discarded. This precaution was undertaken in order to avoid contamination of the sample with epithelial cells from the skin during sample collection. PBMC were isolated with Ficoll-Hypaque density gradient (d=1,077g/mol) centrifugation at 660g for 30min. PBMC were washed three times with PBS and centrifuged at 470g for 10min. Aliquots of 250,000 cells were centrifuged at 400g for 2 min on glass slides (Superfrost Plus). Cytospins were dried up and stored at -80 0 C.
Four slides were analyzed from the same blood sample. For all these cytospins DNA was isolated and BRMS1 promoter methylation was evaluated by methylation specific PCR.
All patients signed an informed consent to participate in the study that was approved by the Ethics and Scientific Committees of our Institutions.
DNA isolation from FFPEs
Τissue sections of 10 μm containing >80% of tumor cells were used for DNA extraction and methylation-specific PCR (MSP) [21] . The breast cancer cell line MCF-7 was used as positive control in MSP reactions for the detection of BRMS1 promoter methylation as previously described [20] . Genomic DNA (gDNA) from both FFPEs and MCF-7 was isolated with the High Pure PCR Template Preparation kit (Roche, Germany) as previously described [20] . DNA concentration was determined in the Nanodrop ND-1000 spectrophotometer (Nanodrop Technologies, USA). Control cytospins were first analysed with confocal laser scanning microscope module (Leica Lasertechnik, Heidelberg, Germany) and with ARIOL system (Genetix, New Milton, UK) for the evaluation of immunofluorescence. Consequently patients samples were analysed for the expression status of CK and BRMS1 in CTC using the ARIOL analysis system (Genetix, New Milton, UK) as previously described [22] [23] [24] . 
Double staining experiments for BRMS1 and pan-cytokeratin A45/B-B3 in CTC

DNA isolation from cytospin stained CTC
Initially, in order to evaluate the efficacy of DNA isolation from cytospin stained CTC we first performed control experiments using MCF-7 cells immobilized on cytospins as a positive control for the whole process including the first step of isolation of CTC from glass slides up to the final step of methylation specific PCR.
In order to diffuse CTC from the cytospins, 500 μL of cold PBS were added on the surface of glass slides containing the immobilized CTC and incubated for 3-4 min at room temperature. Then, CTC were removed from the glass slides by scrapping with a plastic tip. Τhe isolated cell pellet in PBS was centrifuged at 530g for 10 min, prior to DNA extraction. CTC were resuspended in 200 μL PBS and then were used for DNA extraction. Genomic DNA (gDNA) from both CTC and MCF-7 cells immobilized on cytospins was isolated with the High Pure PCR Template Preparation kit (Roche, Germany) using the protocol for isolation of nucleic acids from mammalian whole blood or cultured cells as described [20] . DNA concentration was determined in the Nanodrop ND-1000 spectrophotometer (Nanodrop Technologies, USA). Samples containing 500 pg-2 μg of DNA extracted from FFPE and cytospins were modified with sodium bisulfite (SB), in order to convert all unmethylated, but not methylated-cytosines to uracil. SB conversion was carried out using the EZ DNA Methylation Gold Kit (ZYMO Research Co., Orange, CA), according to the manufacturer's instructions following the short program [20] . The converted DNA was stored at -70 o C until used. In each SB conversion reaction, dH 2 O and MCF-7
were included as a negative and positive control, respectively.
Methylation-specific PCR
BRMS1 promoter methylation was detected by nested MSP by using specific primer pairs for both the methylated and non-methylated BRMS1 promoter sequences. The primer sets for BRMS1 used in this study (Supplementary Table 1 Correlations between BRMS1 promoter methylation status and the clinicopathological features were assessed by using the Chi-square test. Disease-free interval (DFI) and overall survival (OS) curves were calculated by using the Kaplan-Meier method and comparisons were performed using the log rank test. P-values <0.05 were considered statistically significant. Statistical analysis was performed using the SPSS Windows version 19.0 (SPSS, Chicago, IL).
RESULTS
Analytical sensitivity and specificity of BRMS1 promoter MSP assay
The analytical sensitivity of the developed nested MSP assay for BRMS1 promoter was evaluated by initially subjecting 1 μg of fully methylated DNA (100%) and 1 μg of fully unmethylated (100%) human placental genomic DNA to SB conversion.
Synthetic mixtures based on serial dilutions of these SB converted DNA samples were prepared containing various percentages of methylation (0.1%, 1%, 10% and 50%) and 1 μL of these samples were used in the MSP reaction. As can be seen in Figure   2A , by using nested MSP we could detect methylated BRMS1 promoter sequences with a sensitivity of 0.1%, in the presence of 99.9% unmethylated BRMS1 promoter sequences.
To validate the analytical specificity of BRMS1 nested MSP, methylated primers were initially tested in silico and then in PCR, using SB modified human placental gDNA that was not methylated (negative control), unconverted DNA, DNA extracted from the MCF-7 cell line and our positive control (100% methylated DNA); As can be seen in Figure 2B no amplification of BRMS1 promoter could be observed in the first two controls, while both MCF-7 cells and our positive control gave the expected bands;
The specificity of BRMS1 promoter methylation was further confirmed by performing nested MSP in FFPEs obtained from 5 pairs of breast tumors and their surrounding non-cancerous tissues, 14 non-cancerous breast tissues (histologically cancer-free specimens from reduction mammoplasty) and 10 benign breast tumors (fibroadenomas), that were also included as a separate benign tumor group.
MSP with primers specific for the unmethylated DNA was also performed for all SB converted samples to exclude false negative cases, e.g., negative MSP reactions (specific for the methylated DNA sequences) that could be due to bad quality of DNA. By using this quality control approach, BRMS1 promoter was found to be nonmethylated in all these non-cancerous tissues.
BRMS1 methylation in DNA isolated from primary breast tumors
Using the above described highly specific and sensitive nested MSP assay, we examined BRMS1 promoter methylation in 84 operable breast cancer FFPEs.
Methylation of BRMS1 promoter was observed in 0/19 (0%) noncancerous breast tissues, in 0/10 (0%) fibroadenomas and in 31/84 (36.9 %) breast tumors. BRMS1 methylation status in the primary tumors in respect to the clinical characteristics of the patients are shown in Table 1 . As can be seen in Table 1 Using nested MSP, we examined BRMS1 promoter methylation in DNA isolated from these identical cytospin CTC samples which were also tested for non-methylated BRMS1 in order to check their DNA quality. As shown in 
methylation was observed in 5/39 (12.8%) samples, while in the remaining samples BRMS1 non-methylated sequences were observed. This was expected, since cytospins also included PBMC. By immunofluorescence, BRMS1 protein was not expressed in eight samples, while 4/5 samples that were found positive in MSP for BRMS1 promoter methylation did not express BRMS1. In two samples where BRMS1 was expressed at a very low level, BRMS1 promoter methylation was not observed, while four CTC samples had no BRMS1 expression or promoter methylation. In Figure 3D a heat map showing the expression of BRMS1 and BRMS1 promoter methylation in CTC isolated from the same cytospins is presented.
Disease relapse and disease-free survival
After a median follow-up of 121 months (range 58-157), 27/84 (32.1%) patients relapsed and BRMS1 methylation was detected in 15/27 (55.6%) of these patients. The incidence of relapses was significantly higher in patients with methylated (15/31=48.4%) than in patients with non-methylated BRMS1 promoter (12/53=22.6%). Even using these limited cases, the diagnostic sensitivity of BRMS1 methylation for prediction of relapses was estimated as 55.6% (15/27) and the diagnostic specificity was 71.9% (41/57), respectively. It is interesting to note that the Kaplan-Meier estimates of the cumulative DFI for patients with methylated and nonmethylated BRMS1 promoter were significantly different in favor of patients with non-methylated BRMS1 promoter (p=0.009) ( Figure 4A ). During the follow-up period, 19/84 (22.6%) patients died as a consequence of disease progression and BRMS1 methylation was detected in 10/19 (52.6%) of these patients.
Overall survival
The incidence of deaths was higher in patients with methylated BRMS1 promoter (10/31=31.3%) than in patients with non-methylated BRMS1 promoter (9/53=17.0%).
Diagnostic sensitivity of BRMS1 methylation for prediction of deaths was estimated as 52.6% (10/19) and the diagnostic specificity as 66.7% (44/66) respectively. The Kaplan-Meier estimates of the cumulative OS for patients with methylated and nonmethylated BRMS1 promoter were not significantly different in favor of patients with non-methylated BRMS1 promoter however there was a trend (p= 0.071; Figure 4B ).
DISCUSSION
We examined for the first time the relationship between epigenetic silencing of BRMS1 and clinical outcome in operable breast cancers and evaluated the expression of BRMS1 protein and BRMS1 methylation status in CTC using a highly sensitive and specific MSP assay for BRMS1 promoter methylation [20] . BRMS1 promoter methylation was detected only in primary breast tumors but never in normal breast or benign breast disease. BRMS1 promoter methylation in the primary tumor predicted poorer disease-free survival. We could not analyze these primary tumors both for BRMS1 protein and BRMS1 promoter methylation, since the amount of available sample was very limited. For this reason, we preferred to perform BRMS1 methylation analysis in these samples, since the prognostic significance of BRMS1 promoter methylation has not been shown till now.
About half of the patients from which FFPE samples were used had corresponding available peripheral blood samples that were used to isolate pancytokeratin positive-CTC, which were fixed in cytospins. We have assessed both BRMS1 expression and BRMS1 methylation status in these identical cytospins, so that there would be no bias in CTC isolation. More specifically, we first evaluated BRMS1 protein expression status by immunofluorescence in the Ariol system, by using BRMS1 specific Ab, and then we used the same cytospins to detach all cells and extract their DNA. It was this DNA sample that was further used in MSP reactions to evaluate for BRMS1 promoter methylation. BRMS1 expression in CTC was highly heterogeneous, between patients and even in the same patient. This was expected as heterogeneity of CTCs has already been reported for many other markers in many studies up to now mainly at the gene expression level [27] [28] [29] [30] [31] .
Besides this observation, it is interesting that the majority of the analysed CTC (80.5%) were negative for BRMS1 or maintain low expression, as quantified with the Ariol system, implying that BRMS1 is down regulated in these cells. This assumption was confirmed by the fact that four out of five patients, who had methylated BRMS1 promoter, were negative for BRMS1 expression in their CTC. Furthermore, the number of patients who displayed CTC with exclusively high expression of BRMS1 (comparable to PBMCs level) was rather low (28.6%). This high BRMS1 expression in CTC could be related to a good prognosis group of patients, nevertheless, due to the small number of available samples this remains to be explored in the future. 
patients for the first time. According to our results, CTC were highly heterogeneous in respect to BRMS1 expression even in the same patient. Furthermore CTC expressing epithelial markers but no BRMS1 are identified in patients with breast cancer and probably seem to identify patients with worse prognosis. According to our results, BRMS1 promoter methylation provides important prognostic information for disease free survival in early breast cancer. 
